ResearcherJohns Hopkins UniversityNo recent work listed
Nancy R. Porter
Matched on ORCID iD 0000-0003-3548-2460; OpenAlex author ID A5030746879. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2021: 3 papers · 2022: 1 paper
Papers 4
- Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. Co-author DOI 10.1093/jnci/djac167↗
- Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. Co-author DOI 10.1001/jamaoncol.2021.3701↗
- Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. First author DOI 10.1016/j.pan.2021.03.015↗
- A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. Co-author DOI 10.1038/s41416-021-01580-x↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Alison P. Klein · 4 shared papers, 2021–2022 · strength 0.48
- Paper Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. DOI 10.1093/jnci/djac167↗
- Paper Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. DOI 10.1016/j.pan.2021.03.015↗
- Paper Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. DOI 10.1001/jamaoncol.2021.3701↗
- Michael Goggins · 4 shared papers, 2021–2022 · strength 0.48
- Paper Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. DOI 10.1093/jnci/djac167↗
- Paper Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. DOI 10.1016/j.pan.2021.03.015↗
- Paper Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. DOI 10.1001/jamaoncol.2021.3701↗
- Ralph H. Hruban MD · 4 shared papers, 2021–2022 · strength 0.48
- Paper Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. DOI 10.1093/jnci/djac167↗
- Paper Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. DOI 10.1016/j.pan.2021.03.015↗
- Paper Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. DOI 10.1001/jamaoncol.2021.3701↗
- Nicholas Jason Roberts · 3 shared papers, 2021–2022 · strength 0.37
- Paper Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. DOI 10.1093/jnci/djac167↗
- Paper Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. DOI 10.1016/j.pan.2021.03.015↗
- Paper Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. DOI 10.1001/jamaoncol.2021.3701↗
- Jin Peng He · 2 shared papers, 2021–2022 · strength 0.26
- Daniel A. Laheru · 2 shared papers, 2021–2022 · strength 0.26
- Erica J. Childs · 2 shared papers, 2021 · strength 0.23
- Kari G. Rabe · 2 shared papers, 2021 · strength 0.23
- Ayelet Borgida · 2 shared papers, 2021 · strength 0.23
- Sapna Syngal · 2 shared papers, 2021 · strength 0.23
- Steve Gallinger · 2 shared papers, 2021 · strength 0.23
- Gloria M. Petersen · 2 shared papers, 2021 · strength 0.23
- Marcia Irene Canto · 1 shared paper, 2022 · strength 0.14
- Lei Zheng · 1 shared paper, 2022 · strength 0.14
- Amol Kumar Narang · 1 shared paper, 2022 · strength 0.14
- Anne Marie Lennon · 1 shared paper, 2022 · strength 0.14
- Bo Huang · 1 shared paper, 2021 · strength 0.12
- Cancan Zhou · 1 shared paper, 2021 · strength 0.12
- Fang‐Chi Hsu · 1 shared paper, 2021 · strength 0.11
- Amanda L. Blackford · 1 shared paper, 2021 · strength 0.11
- Giovanni Parmigiani Gp · 1 shared paper, 2021 · strength 0.11
- George Zogopoulos · 1 shared paper, 2021 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.